Sumitomo Mitsui Financial Group Inc. Boosts Stock Position in Boston Scientific Corporation $BSX

Sumitomo Mitsui Financial Group Inc. raised its position in Boston Scientific Corporation (NYSE:BSX) by 12.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 265,781 shares of the medical equipment provider’s stock after acquiring an additional 30,300 shares during the quarter. Sumitomo Mitsui Financial Group Inc.’s holdings in Boston Scientific were worth $25,948,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC increased its position in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the period. Ashton Thomas Private Wealth LLC increased its stake in shares of Boston Scientific by 74.8% during the second quarter. Ashton Thomas Private Wealth LLC now owns 11,607 shares of the medical equipment provider’s stock worth $1,247,000 after buying an additional 4,966 shares during the period. Motco lifted its stake in Boston Scientific by 65.8% in the second quarter. Motco now owns 534 shares of the medical equipment provider’s stock worth $56,000 after acquiring an additional 212 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its holdings in Boston Scientific by 72.9% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 344 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 145 shares during the last quarter. Finally, Daymark Wealth Partners LLC boosted its position in shares of Boston Scientific by 24.9% during the 2nd quarter. Daymark Wealth Partners LLC now owns 4,820 shares of the medical equipment provider’s stock worth $518,000 after acquiring an additional 961 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 3.1%

Shares of BSX opened at $75.77 on Friday. The company’s fifty day moving average is $87.69 and its two-hundred day moving average is $95.83. Boston Scientific Corporation has a fifty-two week low of $72.69 and a fifty-two week high of $109.50. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The firm has a market cap of $112.43 billion, a PE ratio of 39.06, a price-to-earnings-growth ratio of 1.02 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company’s revenue was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on BSX. Stifel Nicolaus dropped their target price on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating on the stock in a research report on Wednesday, February 4th. Truist Financial lowered their price objective on shares of Boston Scientific from $120.00 to $95.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. UBS Group dropped their price objective on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. Citigroup dropped their price target on Boston Scientific from $130.00 to $102.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. Finally, JPMorgan Chase & Co. decreased their price objective on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $108.36.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.